Literature DB >> 22681254

Biased agonism of the angiotensin II type 1 receptor.

C M Godin1, S S G Ferguson.   

Abstract

G protein-coupled receptors (GPCRs) can be activated by multiple ligands and exhibit the capacity to couple to numerous intracellular signal transduction pathways. This property allows GPCRs to be modulated by biased agonists that selectively activate specific subsets of GPCR-regulated cellular signaling proteins. The angiotensin II type 1 receptor (AT1R) is a GPCR that endogenously binds to the peptide ligand angiotensin II. More recently it has been demonstrated that a modified peptide, [Sar1I-le4-Ile8]-angiotensin II (SII) acts as a biased agonist towards the AT1R. SII binds to the AT1R without promoting heterotrimeric G protein-coupling, but serves to link the receptor to the beta-arrestin-dependent activation of the mitogen activated protein kinase pathway. The present mini-review summarizes current knowledge regarding the role of biased agonists in stimulating biased AT1R signaling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22681254     DOI: 10.2174/138955712800959134

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  11 in total

Review 1.  A 5'-upstream short open reading frame encoded peptide regulates angiotensin type 1a receptor production and signalling via the β-arrestin pathway.

Authors:  Gina L C Yosten; Jun Liu; Hong Ji; Kathryn Sandberg; Robert Speth; Willis K Samson
Journal:  J Physiol       Date:  2015-10-13       Impact factor: 5.182

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

3.  Saralasin and Sarile Are AT2 Receptor Agonists.

Authors:  Marie-Odile Guimond; Mathias Hallberg; Nicole Gallo-Payet; Charlotta Wallinder
Journal:  ACS Med Chem Lett       Date:  2014-08-18       Impact factor: 4.345

4.  Novel high molecular weight albumin-conjugated angiotensin II activates β-arrestin and G-protein pathways.

Authors:  Hong Weng Pang; Andrea Linares; Leena Couling; Jessica Santollo; Leonardo Ancheta; Derek Daniels; Robert C Speth
Journal:  Endocrine       Date:  2019-04-24       Impact factor: 3.633

Review 5.  Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.

Authors:  G R Kolar; S M Grote; G L C Yosten
Journal:  J Intern Med       Date:  2016-06-16       Impact factor: 8.989

6.  Investigation of the fate of type I angiotensin receptor after biased activation.

Authors:  Gyöngyi Szakadáti; András D Tóth; Ilona Oláh; László Sándor Erdélyi; Tamas Balla; Péter Várnai; László Hunyady; András Balla
Journal:  Mol Pharmacol       Date:  2015-03-24       Impact factor: 4.436

7.  Selective inhibition of angiotensin receptor signaling through Erk1/2 pathway by a novel peptide.

Authors:  Jun Liu; Gina L C Yosten; Hong Ji; Dan Zhang; Wei Zheng; Robert C Speth; Willis K Samson; Kathryn Sandberg
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-02-12       Impact factor: 3.619

Review 8.  Biased signaling of protease-activated receptors.

Authors:  Peishen Zhao; Matthew Metcalf; Nigel W Bunnett
Journal:  Front Endocrinol (Lausanne)       Date:  2014-05-13       Impact factor: 5.555

9.  Transcriptional network analysis reveals that AT1 and AT2 angiotensin II receptors are both involved in the regulation of genes essential for glioma progression.

Authors:  Hátylas Azevedo; André Fujita; Silvia Yumi Bando; Priscila Iamashita; Carlos Alberto Moreira-Filho
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

10.  Src is required for mechanical stretch-induced cardiomyocyte hypertrophy through angiotensin II type 1 receptor-dependent β-arrestin2 pathways.

Authors:  Shijun Wang; Hui Gong; Guoliang Jiang; Yong Ye; Jian Wu; Jieyun You; Guoping Zhang; Aijun Sun; Issei Komuro; Junbo Ge; Yunzeng Zou
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.